Yapay Zeka Hızlı Bakış & Çıkarımlar
AI InsightIn multivariate analysis, PTX3 (OR=1.12, 95% CI 1.04-1.20; p=0.001) was a significant independent predictor of long-term cardiovascular mortality, after adjusting for other risk factors.Conclusion: PTX3 is a novel biomarker that may help to identify high risk individuals with AMI, who are potentially at risk of early major adverse cardiovascular events including mortality in the long-term period.
📌 3 Maddede Bu Makale
Abstract
Objective: A predictive role of serum Pentraxin 3 (PTX3) for short-term adverse cardiovascular events including mortality in acute myocardial infarction (AMI) was reported in recent studies. The aim of the study was to investigate long-term prognostic significance of serum PTX3 in an AMI with 5-year follow-up period in this study.Methods: In this prospective study, 140 patients, who were admitted to the emergency department between January 2011 and December 2011 with acute chest pain and/or dyspnea and diagnosed with AMI and 60 healthy controls were included. PTX3 levels were measured at admission by using an ELISA method. The study group was divided into tertiles on the basis of admission PTX3 values: the high-PTX3 group (>=4.27 ng/mL), the middle-PTX3 groups (4.27-1.63 ng/mL), and the low-PTX3 group (<=1.63 ng/mL).Results: PTX3 level was significantly more greatly increased in the AMI group than in the controls (2.27±0.81 vs. 0.86±0.50 ng/mL, p<0.001). PTX3 level was found to be significantly positively correlated with TIMI score (r=0.368, p=0.037), high sensitive C-reactive protein (hsCRP) (r=0.452, p=0.024), pro-BNP (r=0.386, p=0.029), troponin I (r=0.417, p=<0.001), and GRACE score (r=0.355, p=0.045), and negatively correlated with HDL cholesterol (r=-0.203, p=0.016) and LVEF (r=-0.345, p=0.028). In multivariate analysis, PTX3 (OR=1.12, 95% CI 1.04-1.20; p=0.001) was a significant independent predictor of long-term cardiovascular mortality, after adjusting for other risk factors.Conclusion: PTX3 is a novel biomarker that may help to identify high risk individuals with AMI, who are potentially at risk of early major adverse cardiovascular events including mortality in the long-term period.